Pathogenesis of lung disease in cystic fibrosis
- PMID: 10705255
- DOI: 10.1159/000029453
Pathogenesis of lung disease in cystic fibrosis
Abstract
Lung disease in cystic fibrosis is primarily due to a defect in the cystic fibrosis transmembrane regulating protein (CFTR). This results in abnormal chloride transfer across epithelial membranes causing an excessively viscid mucus lining of the airways. Bacterial invasion particularly with Staphylococcus aureus, Haemophilus influenzae and Pseudomonas aeruginosa stimulates a vigorous and excessive primarily neutrophil-driven inflammatory response throughout the lungs. Products of this inflammation not only damage incoming bacteria but also the host tissue itself. Over a period of years this chronic suppurative process results in permanent ongoing lung destruction principally manifested as bilateral bronchiectasis.
Copyright 2000 S. Karger AG, Basel
Similar articles
-
Opportunities for the use of aerosolized alpha 1-antitrypsin for the treatment of cystic fibrosis.Chest. 1996 Dec;110(6 Suppl):256S-260S. doi: 10.1378/chest.110.6_supplement.256s. Chest. 1996. PMID: 8989161 Review.
-
Protease-antiprotease imbalance in the lungs of children with cystic fibrosis.Am J Respir Crit Care Med. 1994 Jul;150(1):207-13. doi: 10.1164/ajrccm.150.1.7912987. Am J Respir Crit Care Med. 1994. PMID: 7912987
-
Ceramide in cystic fibrosis.Handb Exp Pharmacol. 2013;(216):265-74. doi: 10.1007/978-3-7091-1511-4_13. Handb Exp Pharmacol. 2013. PMID: 23563661 Review.
-
CFTR-dependent susceptibility of the cystic fibrosis-host to Pseudomonas aeruginosa.Int J Med Microbiol. 2010 Dec;300(8):578-83. doi: 10.1016/j.ijmm.2010.08.011. Epub 2010 Oct 14. Int J Med Microbiol. 2010. PMID: 20951085 Review.
-
MPB-07 reduces the inflammatory response to Pseudomonas aeruginosa in cystic fibrosis bronchial cells.Am J Respir Cell Mol Biol. 2007 May;36(5):615-24. doi: 10.1165/rcmb.2006-0200OC. Epub 2006 Dec 29. Am J Respir Cell Mol Biol. 2007. PMID: 17197571
Cited by
-
Inhaled mannitol for cystic fibrosis.Cochrane Database Syst Rev. 2018 Feb 9;2(2):CD008649. doi: 10.1002/14651858.CD008649.pub3. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2020 May 1;5:CD008649. doi: 10.1002/14651858.CD008649.pub4. PMID: 29424930 Free PMC article. Updated.
-
Is it Worth Adding Systemic Antibiotics to Inhalational Tobramycin Therapy to Treat Pseudomonas Infections in Cystic Fibrosis?Cureus. 2021 Aug 20;13(8):e17326. doi: 10.7759/cureus.17326. eCollection 2021 Aug. Cureus. 2021. PMID: 34567873 Free PMC article. Review.
-
N-glycosylation augmentation of the cystic fibrosis epithelium improves Pseudomonas aeruginosa clearance.Am J Respir Cell Mol Biol. 2011 Jun;44(6):824-30. doi: 10.1165/rcmb.2009-0285OC. Epub 2010 Aug 6. Am J Respir Cell Mol Biol. 2011. PMID: 20693405 Free PMC article.
-
Inhaled mannitol for cystic fibrosis.Cochrane Database Syst Rev. 2020 May 1;5(5):CD008649. doi: 10.1002/14651858.CD008649.pub4. Cochrane Database Syst Rev. 2020. PMID: 32358807 Free PMC article.
-
Amelioration of airway and GI disease in G551D-CF ferrets by AAV1 and AAV6.Gene Ther. 2024 Sep;31(9-10):499-510. doi: 10.1038/s41434-024-00469-7. Epub 2024 Jul 28. Gene Ther. 2024. PMID: 39069560
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical